Newark, DE, Nanjing CN – Dec 10, 2020. Biosion Inc. (“Biosion”) today announced completion of ¥200 Million RMB (~$30 Million USD) of financing to transition Biosion into a clinical stage company within twelve months. The financing was led by Lapam Capital, joined by Kaiyuan Capital, Oceanpine Healthcare Fund, C&D Emerging Industry Equity Investment, and Zheshang Innovest.

“We are very grateful to the investors for their confidence and support in our innovative pipeline portfolio, our proprietary integrated technology platforms, as well as our senior management team. Funds from this round of financing will be used to support global clinical development of our innovative pipelines, and to strengthen our preclinical development capabilities of innovative discovery engine.” said Dr. Mingjiu Chen, Founder, Chairman and CEO of Biosion.

Mr. Zhihua Yu, the Chairman of Lapam Capital, said: “We are very optimistic for Biosion’s unique and differentiated innovation pipeline, their highly competitive technology platforms, and their development team with global pharmaceutical experience. We look forward to helping Biosion develop its innovative medicines to benefit patients world-wide.”

Biosion’s Chief Operating Officer and member of the Board of Directors, former Vice President of Janssen Pharmaceuticals, Dr. Hugh Davis said: “With our portfolio of over a dozen high-quality preclinical assets from our unique discovery platforms, we are confident that we will be able to quickly advance the global IND filing and clinical development, thus transforming Biosion into a clinical stage biotech company.”